Title of article :
The Three P’s: Parotid, PD-L1, and Pembrolizumab
Author/Authors :
Kerns, Tamie Tripler Army Medical Cente - Jarrett White Road - DHCK-DM- Honolulu - HI , USA , Wiggins, Amanda Tripler Army Medical Cente - Jarrett White Road - DHCK-DM- Honolulu - HI , USA , Arter, Zhaohui Tripler Army Medical Cente - Jarrett White Road - DHCK-DM- Honolulu - HI , USA
Abstract :
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpointinhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use inundifferentiated carcinoma of the parotid.
Keywords :
Three P’s , Parotid , PD-L1 , Pembrolizumab , platinum-refractory undifferentiated carcinoma , FNA
Journal title :
Case Reports in Oncological Medicine
